Pirtobrutinib in the Management of R/R CLL: Updates from the BRUIN Trial
October 29th 2024Panelists discuss how the non-covalent BTK inhibitor pirtobrutinib has shown promising results in the BRUIN clinical trials for both BTK inhibitor-naive and previously treated chronic lymphocytic leukemia patients, reviewing key efficacy and safety data presented at recent hematology conferences.
Read More
Assessing Resistance to First-Line BTK Inhibitor Therapy: The Emergine Role of Testing in CLL
October 29th 2024Panelists discuss how they assess patients for resistance to first-line BTK inhibitor therapy in chronic lymphocytic leukemia, emphasizing the importance of clinical evaluation, laboratory testing, and genetic analysis in determining the presence and mechanisms of resistance to guide subsequent treatment decisions.
Read More
Tailoring Treatment Approaches for Rapid vs. Slow Disease Progression in CLL
October 22nd 2024Panelists discuss how treatment approaches are tailored differently for patients with rapid, aggressive chronic lymphocytic leukemia progression versus those with slower, less aggressive disease, considering factors such as urgency of intervention, choice of therapy intensity, and long-term management strategies.
Read More
Key Patient-Specific Factors Guiding Treatment Selection in CLL
October 22nd 2024Panelists discuss how various patient-specific factors, including age, comorbidities, performance status, disease aggressiveness, symptoms, and biomarkers, are carefully considered to guide the selection of optimal treatment strategies for individuals with chronic lymphocytic leukemia (CLL).
Read More
Impact of Prior BTKi vs BCL2i Therapy on Treatment Decision-Making in CLL
October 15th 2024Panelists discuss how the choice of prior therapy between BTK inhibitors and BCL2 inhibitors influences subsequent treatment decisions in chronic lymphocytic leukemia (CLL), considering factors such as resistance mechanisms, toxicity profiles, and patient-specific characteristics.
Read More
Future Perspectives on the Treatment Landscape for CLL
A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.
Read More
Expert Insights into Investigation Therapies for CLL
Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.
Read More
Emerging Data Surrounding Mechanisms of Resistance to Non-Covalent BTKis
The expert panel discusses recent data regarding the mechanisms of resistance to non-covalent BTK inhibitors in CLL.
Read More
Role of Non-Covalent BTKis in R/R CLL: Updates from Ongoing BRUIN and Bellwave Trials
Jacqueline Barrientos, MD, MS, discusses the role of non-covalent BTK inhibitors in R/R CLL and provided concise comments on the latest data, including insights from the ongoing BRUIN and Bellwave trials.
Read More
Treatment Resistance with Covalent BTKis: Translating Data into Clinical Practice
Javier Pinilla, MD, PhD explores evidence on molecular mechanisms leading to resistance in second-generation BTK inhibitors for CLL, providing insights from recently presented data at ASH 2023.
Read More
Expert Insights into Navigating Cardiovascular Risks with BTKi Therapy
A panel of expert oncologists explore the influence of hypertension risk and other cardiovascular AEs in guiding treatment selection with BTKis, sharing insights from ASH 2023.
Read More
Expert Perspectives on Navigating Treatment Selection with BTKis in CLL
Faculty provide insights into the selection of BTK inhibitors, emphasizing the role of efficacy, toxicity, and quality of life data in treatment decisions, and exploring the impact of MAIC data.
Read More
Navigating BTKi Therapy in R/R CLL: Updates from ELEVATE-RR and ALPINE
Panel experts examine considerations for BTKi-based strategies in R/R CLL, highlighting pivotal findings from head-to-head trials, including acalabrutinib vs ibrutinib in ELEVATE-RR and zanubrutinib vs ibrutinib in ALPINE, covering safety, quality of life, and extended follow-up data.
Read More
Treatment Sequencing Strategies for R/R CLL: Impact of Prior 1L Therapy
Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.
Read More
Exploring the Role of BTKi-Based Combination Therapies for Front-line Management of CLL
Experts explore the role of BTKi-based combination therapy in the front-line treatment of CLL, focusing on patient considerations and referencing key data from CAPTIVATE, FLAIR, MAJIC, and SEQUOIA (Arm D).
Read More
Impact of Off-Target AEs and Treatment Resistance on Evolving 1L Therapy Strategies for CLL
Javier Pinilla, MD, PhD, provides a brief overview of the changing CLL treatment landscape, discussing the influence of off-target adverse events and the development of treatment resistance on the evolution of BTK inhibitor therapy.
Read More
Strategies for Managing Treatment-Naïve CLL with High-Risk Features
Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.
Read More
Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA
Brian Hill, MD, PhD, discusses the use of BTK inhibitor monotherapy in CLL and presented recent long-term data updates from studies such as the 6-year follow-up of ELEVATE-TN and the extended follow-up from SEQUOIA.
Read More
Current Front-Line Treatment Options for CLL in 2023
Catherine Coombs, MD discusses the present CLL front-line treatment landscape, addressing considerations like choosing fixed-duration or continuous therapy and variations in first-line approaches based on age and ECOG status.
Read More
Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care
Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.
Read More
Management of Diffuse Large B-Cell Lymphoma: Data From ASCO 2023
Key opinion leaders reflect on data from the 2023 ASCO meeting and how it may impact the management of diffuse large B-cell lymphoma.
Read More
Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting
Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.
Read More
Bridging Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Before closing out their discussion on the relapsed/refractory setting of diffuse large B-cell lymphoma, panelists identify best practices in bridging therapy.
Read More
Sequencing Novel Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Comprehensive insight on the optimal sequencing of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
What is the Role of Bispecifics in Relapsed/Refractory DLBCL?
Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.
Read More
Relapsed/Refractory DLBCL: Managing Patients on CAR T-Cell Therapy
A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.
Read More
Factors That Inform Sequencing of Therapy in Relapsed/Refractory DLBCL
Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Real-World Use of CAR T-Cell Therapy in Relapsed/Refractory DLBCL
Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Read More